search
Back to results

Restrictive vs. Liberal Oxygen in Trauma (TRAUMOX2)

Primary Purpose

Trauma, Oxygen Toxicity, Wounds and Injuries

Status
Active
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Restrictive oxygen
Liberal oxygen
Sponsored by
Rigshospitalet, Denmark
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Trauma focused on measuring Trauma, Oxygen

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients aged ≥18 years, including fertile women
  • Blunt or penetrating trauma mechanism
  • Direct transfer from the scene of accident to one of the participating trauma centers
  • Trauma team activation
  • The enrolling physician must initially expect a hospital length of stay for 24 hours or longer

Exclusion Criteria:

  • Patients in cardiac arrest before or on admission
  • Patients with a suspicion of carbon monoxide intoxication
  • Patients with no/minor injuries after secondary survey will be excluded if they are expected to be discharged <24 hours

Sites / Locations

  • Aarhus University Hospital
  • Rigshospitalet, Copenhagen University Hospital
  • Odense University Hospital
  • Erasmus MC, University Medical Center Rotterdam
  • Inselspital University Hospital Bern

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Restrictive oxygen

Liberal oxygen

Arm Description

- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants) and - Only trial participants receiving an FiO2 = 0.21 can saturate >94% Pre-oxygenation as usual prior to intubation is permitted

- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98% or - FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%

Outcomes

Primary Outcome Measures

The incidence of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint)
The assessment of the major respiratory complications will be performed by at least two allocation blinded primary outcome assessors (specialists in anesthesiology, intensive care, emergency medicine or similar); blinding will be ensured by concealing all information indicative of the allocation prior to assessment

Secondary Outcome Measures

30-day mortality
Assessed in the patient's medical record/register
12-month mortality
Assessed in the patient's medical record/register
Major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days
Data from the combined primary endpoint assessment
Hospital length of stay
Number of days
ICU length of stay
Number of days
Time on mechanical ventilation
Number of hours; only mechanical ventilation in the ICU should be considered
Days alive outside the ICU
Number of days
Days alive without mechanical ventilation
Number of days; only mechanical ventilation in the ICU should be considered
Re-intubations
Number of re-intubations; only re-intubations in the ICU should be considered
Pneumonia post-discharge
Number of trial participants; evaluated through medicines prescribed after hospital discharge in countries where this information is available
Episode(s) of hypoxemia during intervention (saturation <90%)
Defined as number of times the valid oxygen saturation is below 90%; if it is below 90%, above 90% and below 90% again, then it should be registered as 2 episodes
Surgical site infections
Defined as per the Centers for Disease Control and Prevention (CDC) criteria for a surgical site infection event
5-level EQ-5D version (EQ-5D-5L) score
Conducted through a telephone interview where the patient is asked to indicate his/her health state The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) The EQ-5D descriptive system consists of a scale (minimum score = 5 and maximum score = 25) where the lowest score (5) indicates no problems whereas the highest score (25) indicates extreme problems The EQ VAS (visual analogue scale) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The worst health you can imagine" (minimum score = 0) and "The best health you can imagine' (maximum score = 100)
The Glasgow Outcome Scale Extended (GOSE) score
Conducted through a telephone interview where the patient/patient's next-of-kin/caretaker is interviewed through a structured questionnaire to assess the functional recovery after trauma The GOSE consists of a scale (minimum value = 1 and maximum value = 8); each patient given a score based on the interview: 1 = Death, 2 = Vegetative state, 3 = Lower severe disability, 4 = Upper severe disability, 5 = Lower moderate disability, 6 = Upper moderate disability, 7 = Lower good recovery, 8 = Upper good recovery
Levels of oxidative stress biomarkers, primarily malondialdehyde (MDA) at hour 24
The unit of the oxidative stress biomarker depends on the chosen analysis of the specific biomarker

Full Information

First Posted
November 30, 2021
Last Updated
October 13, 2023
Sponsor
Rigshospitalet, Denmark
Collaborators
The Novo Nordic Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05146700
Brief Title
Restrictive vs. Liberal Oxygen in Trauma
Acronym
TRAUMOX2
Official Title
Comparing Restrictive vs. Liberal Oxygen Strategies for Trauma Patients: The TRAUMOX2 Trial
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 10, 2021 (Actual)
Primary Completion Date
October 12, 2023 (Actual)
Study Completion Date
June 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Rigshospitalet, Denmark
Collaborators
The Novo Nordic Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Victims of trauma are often healthy individuals prior to the incident, but acquire numerous complications including sepsis and pulmonary complications and diminished quality of life after trauma. According to Advanced Trauma Life Support guidelines, all severely injured trauma patients should receive supplemental oxygen. The objective of TRAUMOX2 is to compare the effect of a restrictive versus liberal oxygen strategy the first eight hours following trauma on the incidence of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint).
Detailed Description
In trauma resuscitation, supplemental oxygen is often administered both to treat and prevent hypoxemia as recommended both by the Advanced Trauma Life Support (ATLS) manual and the Pre-hospital Trauma Life Support (PHTLS) manual. Oxygen is administered in many other situations too, sometimes in a non-consistent manner and very often without even being prescribed. In a recent systematic review, our group found the evidence both for and against the use of supplemental oxygen in the trauma population to be extremely sparse. However, a recent systematic review and meta-analysis comparing liberal versus restrictive oxygen strategy for a broad mix of acutely ill medical and surgical patients found an association between liberal oxygen administration and increased mortality. Of note, only one small study on trauma patients (patients with traumatic brain injury), which did not report mortality data, was included. Conversely, this study showed that degree of disability was significantly reduced at six months in the group receiving liberal compared to restrictive oxygen. In mechanically ventilated patients hyperoxemia is commonly observed (16-50%), and hyperoxemia is a common finding in trauma patients in general. In addition to mortality, hyperoxemia has been associated with major pulmonary complications in the Intensive Care Unit (ICU) as well as in surgical patients. For example, a recent retrospective study found hyperoxemia to be an independent risk factor for ventilator associated pneumonia (VAP). Nevertheless, a highly debated recommendation from the World Health Organisation strongly recommends that adult patients undergoing general anesthesia for surgical procedures receive a fraction of inspired oxygen (FiO2) of 80% intraoperatively as well as in the immediate postoperative period for two to six hours to reduce the risk of surgical site infection. Furthermore, a study on 152,000 mechanically ventilated patients found no association between hyperoxia and mortality during the first 24 hours in the ICU, and another study on 14,000 mixed ICU patients found that a partial arterial oxygen pressure (PaO2) of approximately 18 kPa resulted in the lowest mortality. Finally, a recent study randomized 2928 ICU patients to either low or high oxygenation (defined as 8 vs 12 kPa) for a maximum of 90 days and found no difference in mortality. Therefore, whether the trauma population could benefit from a more restrictive supplemental oxygen approach than recommended by current international guidelines presents a large and important knowledge gap. In a recent pilot randomized clinical trial (TRAUMOX1, ClinicalTrials.gov Registration number: NCT03491644), we compared a restrictive and a liberal oxygen strategy for 24 hours after trauma (N = 41) and found maintenance of normoxemia following trauma using a restrictive oxygen strategy to be feasible. TRAUMOX1 served as the basis for this larger trial. We experienced 24 hours to be slightly excessive to represent only the acute phase post trauma for which reason we have shortened the time-period to eight hours in TRAUMOX2. Furthermore, we found that several physicians had important concerns with the high dosage of oxygen in the liberal arm for which reason the concentration will be reduced. Finally, we did not randomize trauma patients in the pre-hospital phase, but instead on arrival at the trauma bay (median [interquartile range (IQR)] time to randomization: 7 [4-10] minutes, median [IQR] time from trauma to trauma bay arrival: 51 [29.0-67.5] minutes). To limit this inconsistent exposure to oxygen in the pre-hospital phase prior to inclusion we will initiate the intervention in the pre-hospital phase where possible in TRAUMOX2. The objective of TRAUMOX2 is to compare the effect of a restrictive versus liberal oxygen strategy the first eight hours following trauma on the incidence of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint). We hypothesize that a restrictive compared to a liberal oxygen strategy for the initial eight hours after trauma will result in a lower rate of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trauma, Oxygen Toxicity, Wounds and Injuries
Keywords
Trauma, Oxygen

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Trial participants are randomized pre-hospital or in the trauma bay to a restrictive or liberal oxygen treatment for eight hours. Experimental (restrictive oxygen): The restrictive group will receive the lowest dosage of oxygen (≥21%) ensuring an SpO2 target = 94% Active comparator (liberal oxygen): The liberal group will receive a flow of 15 L O2/min for non-intubated trial participants or an FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation; later in the operating room (OR), intensive care unit (ICU), post-anesthesia care unit (PACU) and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation (SpO2) is ≥98%
Masking
Outcomes Assessor
Masking Description
Open-label, primary outcome assessor- and analyst-blinded, randomized, controlled clinical trial with regards to treatment: treating staff will be aware of the trial participants' randomization group. While including patients for the study, the research team and treating staff will be aware of the trial participants' oxygen allocation strategy. However, at least two allocation blinded primary outcome assessors (specialists in anesthesiology, intensive care, emergency medicine or similar) will be appointed at each center to assess in-hospital major lung complications (pneumonia and acute respiratory distress syndrome). Blinding will be ensured by concealing all information indicative of the allocation prior to assessment. The statistician and manuscript writers will be blinded towards the allocation of treatment once the trial ends when data is being analysed and the manuscript is drafted.
Allocation
Randomized
Enrollment
1420 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Restrictive oxygen
Arm Type
Experimental
Arm Description
- Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94% either using no supplemental oxygen, a nasal cannula, a non-rebreather mask or manual/mechanical ventilation (intubated trial participants) and - Only trial participants receiving an FiO2 = 0.21 can saturate >94% Pre-oxygenation as usual prior to intubation is permitted
Arm Title
Liberal oxygen
Arm Type
Active Comparator
Arm Description
- 15 L O2/min flow for non-intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the flow can be reduced to ≥12 L O2/min if the arterial oxygen saturation is ≥98% or - FiO2 = 1.0 for intubated trial participants in the pre-hospital phase, the trauma bay and during intrahospital transportation. In the operating room, intensive care unit, post-anesthesia care unit and ward the FiO2 can be reduced to ≥0.6 if the arterial oxygen saturation is ≥98%
Intervention Type
Drug
Intervention Name(s)
Restrictive oxygen
Intervention Description
Lowest oxygen delivery possible (≥21%) ensuring an SpO2 target = 94%
Intervention Type
Drug
Intervention Name(s)
Liberal oxygen
Intervention Description
15 L O2/min flow for non-intubated trial participants or FiO2 = 1.0 for intubated trial participants in the initial phase; later in the operating room, intensive care unit, post-anesthesia care unit and ward, the flow/FiO2 can be reduced to ≥12 L O2/min or FiO2 ≥0.6 if the arterial oxygen saturation is ≥98%
Primary Outcome Measure Information:
Title
The incidence of 30-day mortality and/or major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days (combined primary endpoint)
Description
The assessment of the major respiratory complications will be performed by at least two allocation blinded primary outcome assessors (specialists in anesthesiology, intensive care, emergency medicine or similar); blinding will be ensured by concealing all information indicative of the allocation prior to assessment
Time Frame
Day 30 after enrollment
Secondary Outcome Measure Information:
Title
30-day mortality
Description
Assessed in the patient's medical record/register
Time Frame
Day 30 after enrollment
Title
12-month mortality
Description
Assessed in the patient's medical record/register
Time Frame
12 months after enrollment
Title
Major respiratory complications (pneumonia and acute respiratory distress syndrome) within 30 days
Description
Data from the combined primary endpoint assessment
Time Frame
Day 30 after enrollment
Title
Hospital length of stay
Description
Number of days
Time Frame
From date of admission to discharge from the hospital, up to 12 months after enrollment
Title
ICU length of stay
Description
Number of days
Time Frame
From date of admission to discharge from the ICU, up to 12 months after enrollment
Title
Time on mechanical ventilation
Description
Number of hours; only mechanical ventilation in the ICU should be considered
Time Frame
From initiation of mechanical ventilation to being ventilator-free within 30 days after enrollment
Title
Days alive outside the ICU
Description
Number of days
Time Frame
ICU-free days within 30 days after enrollment
Title
Days alive without mechanical ventilation
Description
Number of days; only mechanical ventilation in the ICU should be considered
Time Frame
Ventilator-free days within 30 days after enrollment
Title
Re-intubations
Description
Number of re-intubations; only re-intubations in the ICU should be considered
Time Frame
Within 30 days after enrollment
Title
Pneumonia post-discharge
Description
Number of trial participants; evaluated through medicines prescribed after hospital discharge in countries where this information is available
Time Frame
From discharge to a maximum of 30 days after enrollment
Title
Episode(s) of hypoxemia during intervention (saturation <90%)
Description
Defined as number of times the valid oxygen saturation is below 90%; if it is below 90%, above 90% and below 90% again, then it should be registered as 2 episodes
Time Frame
During the 8 hours of the oxygen intervention arms
Title
Surgical site infections
Description
Defined as per the Centers for Disease Control and Prevention (CDC) criteria for a surgical site infection event
Time Frame
Within 30 days after enrollment
Title
5-level EQ-5D version (EQ-5D-5L) score
Description
Conducted through a telephone interview where the patient is asked to indicate his/her health state The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS) The EQ-5D descriptive system consists of a scale (minimum score = 5 and maximum score = 25) where the lowest score (5) indicates no problems whereas the highest score (25) indicates extreme problems The EQ VAS (visual analogue scale) records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled "The worst health you can imagine" (minimum score = 0) and "The best health you can imagine' (maximum score = 100)
Time Frame
6 and 12 months post-trauma
Title
The Glasgow Outcome Scale Extended (GOSE) score
Description
Conducted through a telephone interview where the patient/patient's next-of-kin/caretaker is interviewed through a structured questionnaire to assess the functional recovery after trauma The GOSE consists of a scale (minimum value = 1 and maximum value = 8); each patient given a score based on the interview: 1 = Death, 2 = Vegetative state, 3 = Lower severe disability, 4 = Upper severe disability, 5 = Lower moderate disability, 6 = Upper moderate disability, 7 = Lower good recovery, 8 = Upper good recovery
Time Frame
6 and 12 months post-trauma
Title
Levels of oxidative stress biomarkers, primarily malondialdehyde (MDA) at hour 24
Description
The unit of the oxidative stress biomarker depends on the chosen analysis of the specific biomarker
Time Frame
Hour 0, hour 8, hour 24 and hour 48 after enrollment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients aged ≥18 years, including fertile women Blunt or penetrating trauma mechanism Direct transfer from the scene of accident to one of the participating trauma centers Trauma team activation The enrolling physician must initially expect a hospital length of stay for 24 hours or longer Exclusion Criteria: Patients in cardiac arrest before or on admission Patients with a suspicion of carbon monoxide intoxication Patients with no/minor injuries after secondary survey will be excluded if they are expected to be discharged <24 hours
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jacob Steinmetz, MD, PhD
Organizational Affiliation
Consultant
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Tobias Arleth, MD
Organizational Affiliation
Research assistent
Official's Role
Principal Investigator
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Facility Name
Rigshospitalet, Copenhagen University Hospital
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Facility Name
Erasmus MC, University Medical Center Rotterdam
City
Rotterdam
ZIP/Postal Code
3000
Country
Netherlands
Facility Name
Inselspital University Hospital Bern
City
Bern
ZIP/Postal Code
3010
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Yes
Citations:
PubMed Identifier
36344005
Citation
Baekgaard J, Arleth T, Siersma V, Hinkelbein J, Yucetepe S, Klimek M, van Vledder MG, Van Lieshout EMM, Mikkelsen S, Zwisler ST, Andersen M, Fenger-Eriksen C, Isbye DL, Rasmussen LS, Steinmetz J. Comparing restrictive versus liberal oxygen strategies for trauma patients - the TRAUMOX2 trial: protocol for a randomised clinical trial. BMJ Open. 2022 Nov 7;12(11):e064047. doi: 10.1136/bmjopen-2022-064047.
Results Reference
derived
Links:
URL
https://www.traumox2.org
Description
The official study website of TRAUMOX2

Learn more about this trial

Restrictive vs. Liberal Oxygen in Trauma

We'll reach out to this number within 24 hrs